PlaqueTec, a medtech startup developing intracoronary liquid biopsy technology, has raised £3.7 million in funding from existing investors. The oversubscribed financing round was funded entirely by its existing investor base. The investment will support the continued build-out of its proprietary cardiovascular data lake, BioCarta.
It is building BioCarta as a repository of intracoronary proteomic and clinical data to provide a site-of-disease strategy for understanding inflammatory risk in cardiovascular disease. The platform uses proteomic biomarkers collected directly at the site of plaque formation via its intracoronary liquid biopsy device, generating data that cannot be obtained through conventional systemic blood sampling. This approach is intended to enable more accurate assessment of disease and inform targeted therapeutic interventions.
BioCarta contains data from patient samples collected in the BIOPATTERN trial, which is generating proteomic data across a growing patient cohort. Several potential targets have been identified in sub-groups accounting for the majority of the studied coronary artery disease population. The data lake strategy positions these findings as a platform asset for partnership and licensing with pharmaceutical companies engaged in cardiovascular drug development, and it is engaged in discussions with potential pharmaceutical and biotech partners.
The decision by our existing shareholders to reinvest, and to do so at a level that exceeded our target, speaks directly to their confidence in what PlaqueTec's data is revealing about cardiovascular disease. We are building something genuinely differentiated: a high-resolution, intracoronary data asset that is poised to underpin the next generation of cardiovascular therapeutics. This round validates that strategy and gives us the runway to prove it.
